文献速递肾癌与肾肿瘤

术前C反应蛋白升高与手术治疗肾细胞癌患者肾功能下降及非癌死亡相关:INMARC分析

Elevated preoperative C-reactive protein is associated with renal functional decline and non-cancer mortality in surgically treated renal cell carcinoma: analysis from the INternational Marker Consortium for Renal Cancer (INMARC).
PubMed 文献 · BJU Int · 2020-11-19

该回顾性多中心分析纳入2006至2017年临床分期1-2期行肾部分或根治性切除术的1987例肾细胞癌患者,比较术前CRP正常(≤5 mg/L)与升高(>5 mg/L)两组的非癌死亡和肾功能下降。多变量分析显示术前CRP升高独立关联新发eGFR下降至<60、<45、<30 mL/min/1.73m2及非癌死亡风险增加,CRP升高组5年非癌死亡显著更高(98% vs 80%,P<0.001)。

要点

  • 术前CRP>5 mg/L与术后新发eGFR<60、<45、<30 mL/min/1.73m2风险独立相关。
  • 术前CRP升高是非癌死亡的独立危险因素(HR 2.18,P<0.001)。
  • CRP升高组5年非癌生存率显著低于正常组(98% vs 80%,P<0.001)。

核心结论

  • 术前CRP升高独立关联临床1-2期肾细胞癌术后肾功能进行性下降及非癌死亡。
  • CRP升高且分期1-2期的患者可考虑保留肾单位策略,若肿瘤学允许应优先选择。

研究设计与样本

  • 回顾性多中心分析,纳入2006至2017年临床1-2期行肾部分或根治性切除术的肾细胞癌患者,排除癌症特异性死亡。
  • 共分析1987例,CRP正常组963例,CRP升高组1024例。

主要发现

  • CRP升高组男性比例更高(36.8% vs 27.8%,P<0.001),非裔美国人比例更高(22.6% vs 2.9%,P<0.001),中位BMI更高(30 vs 25 kg/m2,P<0.001),中位肿瘤更大(4.5 vs 3.3 cm,P<0.001)。
  • 多变量分析:CRP升高与新发eGFR<60 mL/min/1.73m2(HR 1.32,P=0.015)、<45 mL/min/1.73m2(HR 1.41,P=0.023)、<30 mL/min/1.73m2(OR 2.23,P<0.001)独立相关。
  • 非癌死亡的多变量分析显示年龄增长(HR 1.06,P<0.001)、术前CRP升高(HR 2.18,P<0.001)和eGFR<45 mL/min/1.73m2(HR 1.16,P=0.021)为独立危险因素。
  • Kaplan-Meier分析显示CRP升高组5年非癌死亡显著高于正常组(98% vs 80%,P<0.001)。

关键数值与推荐

  • CRP正常定义为≤5 mg/L,升高定义为>5 mg/L。
  • 肾功能下降采用eGFR阈值<60、<45、<30 mL/min/1.73m2。

临床怎么用

  • 术前检测CRP有助于识别术后肾功能下降和非癌死亡高风险患者。
  • 对CRP升高且临床1-2期肾细胞癌患者,若肿瘤学允许可优先考虑保留肾单位手术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate association of preoperative C-reactive protein (CRP) and non-cancer mortality (NCM) in a cohort of patients undergoing surgery for localised renal cell carcinoma (RCC). PATIENTS AND METHODS: Retrospective multicentre analysis of patients surgically treated for clinical Stage 1-2 RCC from 2006 to 2017, excluding all cases of cancer-specific mortality. Descriptive analyses were obtained between the pre-treatment normal-CRP (≤5 mg/L) and elevated-CRP (>5 mg/L) groups. The primary outcome was NCM. The secondary outcomes included progression to de novo chronic kidney disease Stages 3-4 (estimated glomerular filtration rate [eGFR] of <60, <45, and <30 mL/min/1.73 m2 ). Multivariable analyses (MVA) were performed to assess for risk factors associated with functional decline and NCM, and Kaplan-Meier analysis was used to obtain survival estimates for outcomes. RESULTS: A total of 1987 patients who underwent radical or partial nephrectomy were analysed (normal-CRP group, n = 963; elevated-CRP group, n = 1024). Groups were similar in age (59 vs 60 years, P = 0.079). An elevated CRP was more frequent in males (36.8% vs 27.8%, P < 0.001), African-Americans (22.6% vs 2.9%, P < 0.001), and in those with a higher median body mass index (30 vs 25 kg/m2 , P < 0.001) and larger median tumour size (4.5 vs 3.3 cm, P < 0.001). On MVA, an elevated CRP was independently associated with development of de novo eGFR of <60 mL/min/1.73 m2 (hazard ratio [HR] 1.32, P = 0.015), <45 mL/min/1.73 m2 (HR 1.41, P = 0.023) and <30 mL/min/1.73 m2 (odds ratio 2.23, P < 0.001). The MVA for factors associated with NCM demonstrated increasing age (HR 1.06, P < 0.001), preoperative elevated CRP (HR 2.18, P < 0.001) and an eGFR of <45 mL/min/1.73 m2 (HR 1.16; P = 0.021) as independent risk factors. Kaplan-Meier analysis revealed significantly higher 5-year NCM in the elevated-CRP group vs the normal-CRP group (98% vs 80%, P < 0.001). CONCLUSIONS: Pre-treatment elevated CRP was independently associated with both progressive renal functional decline and NCM in patients undergoing surgery for Stage 1-2 RCC. Patients with elevated CRP and Stage 1 and 2 RCC may be considered as having indication for nephron-sparing strategies, which may be prioritised if oncologically appropriate.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Cotta BH, Meagher MF, Patil D, et al. Elevated preoperative C-reactive protein is associated with renal functional decline and non-cancer mortality in surgically treated renal cell carcinoma: analysis from the INternational Marker Consortium for Renal Cancer (INMARC). BJU Int. 2020. PMID: 32772468. doi:10.1111/bju.15200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。